Asasantin®
DrugAsasantin® extended release (RAD-SP)
NCT Number: NCT02273479
Study to investigate pharmacokinetics, pharmacodynamics and safety of RAD-SP capsule in multiple administration to healthy adult male volunteers.
Looking for future studies?
Notify Me20 year–35 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Asasantin® extended release (RAD-SP)
Time frame: up to 144 hours after first drug administration
Time frame: up to 144 hours after first drug administration
Time frame: up to 144 hours after first drug administration
Time frame: up to 144 hours after first drug administration
Time frame: up to 144 hours after first drug administration
Time frame: up to 144 hours after first drug administration
Time frame: up to 144 hours after first drug administration
Time frame: up to 144 hours after first drug administration
Time frame: up to 74 hours after first drug administration
Time frame: up to 74 hours after first drug administration
Time frame: up to 74 hours after first drug administration
Time frame: up to 14 days after first drug administration
Time frame: up to 14 days after first drug administration
Time frame: up to 14 days after first drug administration
Time frame: up to 14 days after first drug administration
Boehringer Ingelheim
Industry
Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) 200/25 mg Capsules b.i.d. in Randomised, Double-blind, Placebo-controlled Study in Japanese Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01866852
Healthy
Bethesda, Maryland, United States
View Trial DetailsNCT07515417
Dyssomnias, Health Adult Subjects
Mecca, Saudi Arabia
View Trial DetailsNCT07400679
Body Weight, Healthy
New Haven, Connecticut, United States
View Trial DetailsNCT06972862
Behavior, Exercise
Lawrence, Kansas, United States
View Trial Details